Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational studyResearch in context
Summary: Background: Evidence for the efficacy of nusinersen in adults with 5q-associated spinal muscular atrophy (SMA) has been demonstrated up to a period of 16 months in relatively large cohorts but whereas patients reach a plateau over time is still to be demonstrated. We investigated the effic...
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Elsevier
2024-04-01
|
Edice: | The Lancet Regional Health. Europe |
Témata: | |
On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2666776224000280 |